Skip to content
Screener

Boston Scientific BSX Business Combination, Contingent Consideration, Liability

Business Combination, Contingent Consideration, Liability at other companies

TFX
TeleflexTFX
$47.41M-25.0%
Globus Medical logo
Globus MedicalGMED
$105.39M+0.4%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.45B-53.2%
P/E19.5×-41.6×
P/S3.4×-4.8×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiability.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions)
Balance as of December 31, 2025$385
Contingent consideration net expense (benefit)(30)
Balance as of March 31, 2026$354

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's business combination, contingent consideration, liability?
Boston Scientific (BSX) reported business combination, contingent consideration, liability of $354M in Q1 2026.
How has Boston Scientific's business combination, contingent consideration, liability changed year-over-year?
Boston Scientific's business combination, contingent consideration, liability increased by 65.4% year-over-year, from $214M to $354M.
What is the long-term trend for Boston Scientific's business combination, contingent consideration, liability?
Over 5 years (2020 to 2025), Boston Scientific's business combination, contingent consideration, liability has grown at a 14.5% compound annual growth rate (CAGR), from $196M to $385M.

Ask your AI about Boston Scientific's business combination, contingent consideration, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude